BioSpace

Significant stock movers of October: Biohaven climbs, ArriVent dives

A fresh FDA review for Biohaven’s embattled ataxia drug lifted the biotech's shares, while a late-stage lung cancer miss battered ArriVent, which failed to rebound even after encouraging early ADC data.

By BioSpace

1 min read
Significant stock movers of October: Biohaven climbs, ArriVent dives
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights